Earlier this month, Merck announced that the FDA approved its anti–PD-1 therapy, pembrolizumab (sold as Keytruda), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Earlier this month, Merck announced that the FDA approved its anti—PD-1 therapy, pembrolizumab (sold as Keytruda), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
This new indication was approved under the accelerated approval pathway due to tumor response rate and durability of response as demonstrated in the KEYNOTE-224 trial. However, continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
“Hepatocellular carcinoma is the most common type of liver cancer in adult, and while we have seen recent therapeutic advancements, there are still limited treatment options for advanced recurrent disease,” Andrew Zhu, MD, PhD, lead investigator and director of liver cancer research at Massachusetts General Hospital and professor of medicine at Harvard Medical School, said in a statement.
KEYNOTE-224 is a single-arm, open-label, multicenter study evaluating pembrolizumab in 104 patients with HCC who had disease progression during or after treatment with sorafenib, or who were intolerant to sorafenib. Patients received pembrolizumab 200 mg every 3 weeks until unacceptable toxicity or confirmed disease progression.
The trial found that objective response rate was 17% (95% CI, 11-26), with a complete response rate of 1%, and a partial response rate of 16%. Among the patients who responded to treatment (n = 18), 89% experienced a duration of response for 6 months or longer, and 56% experienced a duration of response for 12 months or longer.
Adverse events occurring in patients with HCC were similar to those seen in patients with melanoma or non-small cell lung cancer, with the exception of increased incidences of ascites (8% grades 3-4), and immune-mediated hepatitis (2.9%).
“We look forward to continuing to advance research for hepatocellular carcinoma across our portfolio with the goal to help even more patients affected by this type of cancer,” said Scot Ebbinghaus, MD, vice president of clinical research at Merck Research Laboratories.
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
November 30th 2023Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Read More
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More
Addressing Financial Toxicity With Navigators and Better Conversations Around Decision Making
June 5th 2018Financial toxicity impacts a lot more than a patient's finances—it leads to nonadherence and poorer health outcomes. Financial navigators are increasingly being used to be proactive about addressing high healthcare costs and the resulting financial toxicity.
Listen
Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
November 1st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Read More